| Attending joint formulation meetings on pharmaceuticals and special medical materials. | Krebs
> Krebs: die meisten Arten | Regulatorische Partnerschaft
> Zusammenarbeit mit Regulierungsbehörden | 100.000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | Krebs
> Krebs: die meisten Arten | Regulatorische Partnerschaft
> Zusammenarbeit mit Regulierungsbehörden | 5.000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Krebs
> Krebs: die meisten Arten | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | 5.000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuskulär
> Spinale Muskelatrophie (SMA) | Regulatorische Partnerschaft
> Teilnahme an Health Technology Assessment (HTA) und Erstattungsprüfungen | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Krebs
> Krebs: die meisten Arten | Regulatorische Partnerschaft
> Teilnahme an/Durchführung von Treffen mit politischen Entscheidungsträgern/Regulierungsbehörden | 5.000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | Krebs
> Krebs: die meisten Arten | Regulatorische Partnerschaft
> Teilnahme an/Durchführung von Treffen mit politischen Entscheidungsträgern/Regulierungsbehörden | 5.000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | Krebs
> Krebs: die meisten Arten | Einfluss auf Politik und Gesetzgebung
> Gesundheitspolitik und Gesetzgebung beeinflussen | 10.000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Krebs
> Krebs: die meisten Arten | Einfluss auf Politik und Gesetzgebung
> An öffentlichen Anhörungen und Konsultationen teilnehmen | 10.000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Allgemeine Gesundheit
> Gesundheitsversorgung | Preisgestaltung und Erschwinglichkeitsförderung
> Für faire Medikamentenpreise eintreten | 5.000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Krebs
> Krebs: Brust | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 10.000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Allgemeine Gesundheit
> Gesundheitsversorgung | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 5.000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Krebs
> Krebs: Neuroendokrin (NET) | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Krebs
> Krebs: die meisten Arten | Preisgestaltung und Erschwinglichkeitsförderung
> Befürwortung der Aufnahme des Produkts in Erstattungslisten/nationale Arzneimittelverzeichnisse | 10.000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Krebs
> Krebs: Brust | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | 10.000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Krebs
> Krebs: Neuroendokrin (NET) | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromuskulär
> Spinale Muskelatrophie (SMA) | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Krebs
> Krebs: die meisten Arten | Verbesserung der Zugangswege
> Gleichberechtigten Zugang zu Medikamenten/Gesundheitsversorgung fördern | 10.000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Krebs
> Krebs: die meisten Arten | Evidenzbasierter Patientenbeitrag
> Nutzen Sie Patienteneinblicke, um Entscheidungen zu treffen | 5.000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | Institutionelle Governance
> Sicherstellen der Vertretung in staatlichen Beratungsgremien | 5.000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Krebs
> Krebs: die meisten Arten | Institutionelle Governance
> Effektiv in Netzwerken mit mehreren Interessengruppen arbeiten | 10.000 | National | Sometimes | 119055308347 |
Interaktionen
Aktionen & Interessenvertretung
5 Erwähnungen
